Safety and efficacy of sintilimab combination therapy for the treatment of 48 patients with advanced malignant tumors

BACKGROUND: Sintilimab is a recombinant fully human anti-programmed death 1 (PD-1) monoclonal antibody that blocks the interaction of PD-1 with its ligand. We evaluated the safety and efficacy of sintilimab combined with chemotherapy and targeted therapy in the treatment of advanced malignant tumors...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Nana, Zhao, Chenchen, Hu, Xueyang, Zhang, Congjun, Xiong, Fuxing, Huang, Wei, Da, Liangshan, Shen, Yuanyuan, Wu, Hongyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841595/
https://www.ncbi.nlm.nih.gov/pubmed/35261901
http://dx.doi.org/10.21037/tcr-22-54

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841595/
https://www.ncbi.nlm.nih.gov/pubmed/35261901
http://dx.doi.org/10.21037/tcr-22-54

Ejemplares similares